Backtested Scanners
AAQS AlleAktien Quality Score
90 Hits · last calculated September 18, 2026 Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · Market filter active: the list shows 0 hits from France
Methodology & criteria
The AAQS (AlleAktien Quality Score) is built on the criteria catalog developed and published by AlleAktien (https://www.alleaktien.com/aaqs). We calculate it independently from our own fundamental data — there is no partnership with AlleAktien. The score checks 10 criteria on growth, profitability, and balance-sheet strength, each worth 1 point: (1) 10-year sales growth above 5% p.a., (2) expected 3-year sales growth above 5% p.a. (analyst estimates), (3) 10-year EBIT growth above 5% p.a., (4) expected 3-year EBIT growth above 5% p.a., (5) net financial debt below 4x EBIT, (6) positive EBIT in every one of the last 10 years, (7) maximum EBIT decline below 50%, (8) tangible return on equity above 15%, (9) ROCE (return on capital employed) above 15%, and (10) expected return (FCF yield plus expected EBIT growth) above 10%. Under AlleAktien's methodology a stock counts as a quality stock from 9 out of 10 points — that is exactly how it is flagged on every stock page. This list is deliberately stricter: it shows only stocks with the full score of 10 out of 10. We back-tested the score over the years for that decision, and the gap between "from 9" and "exactly 10" was clear: in the reliable window from 2010 onwards a portfolio of 10-point stocks returned 17.08% a year, while an S&P 500 ETF returned 14.27% over the same period; the version from 9 points was only 0.77 percentage points ahead of the market. The full calculation with all its limitations is in our back-test study, linked from this page. In fairness: the back-test measures the score, not this scanner — and a measured past is no promise about the future. An honest note on criterion 4: since we don't have access to analysts' EBIT estimates, we use the expected earnings trend (EPS growth estimate) as a proxy for expected EBIT growth. Where that estimate doesn't hold up either — for instance when the most recent earnings per share are negative and no growth rate follows from them — criteria 4 and 10 fall back to the revenue estimate. Equally honest on the time frames: the ten-year criteria (1, 3, 6, and 7) are the benchmark, but not every company has been listed that long — where fewer than 10 but at least 5 fiscal years are available, we calculate over the series we have. If the data needed for a criterion is missing, that isn't automatically counted as passed — it's scored as 0 points and shown greyed out as "no data" in the overview, so it's clear where a gap sits rather than a genuine fail. The AAQS is a pure quality filter: it says nothing about the current share price or a fair valuation, only how robust a company's growth, profitability, and balance sheet have been historically and are expected to be per analyst estimates. A high score is not a buy or return promise. Source: fundamental data.
No global trading filters — this strategy checks the entire stock universe purely against its own criteria (mega caps over $50B included).
🔔 Watch scanner
Hit List
Tip: clicking a column header sorts the table by that column; a second click flips the direction.
| Symbol | AAQS | Acceleration (pp) | Earnings | Avg/Y 3Y | Volatility | Stage | Funda Rating | Piotroski | MktCap | Industry | AI Rating | Deep Dive | Deep-Dive Report | Sector | Price | YTD | 6 Mo. | 1 Year | Off High | Price Target | RS | EPS Rating | ADR 10D | ADR 30D | Beta | P/E | P/E (f) | P/S | P/B | P/FCF | PEG | EV/EBITDA | EBIT Margin | Gross Margin | Net Margin | ROE | ROA | Debt/Eq | Equity Ratio | Sales +/Y | Growth Score | Div. Yield | Payout Ratio | Altman Z | Inst. % | Short % | Analysts |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No stocks currently pass this scanner. | |||||||||||||||||||||||||||||||||||||||||||||||
Frequently Asked Questions
The AAQS (AlleAktien Quality Score) is built on the criteria catalog developed and published by AlleAktien (https://www.alleaktien.com/aaqs). We calculate it independently from our own fundamental data — there is no partnership with AlleAktien.
All scanners are recalculated daily across the entire stock universe — most recently on September 18, 2026. The data basis is fundamental data and SEC filings (10-K annual reports and 10-Q quarterly reports).
Currently, 90 stocks pass this scanner's criteria (as of September 18, 2026).
No global trading filters — this strategy checks the entire stock universe purely against its own criteria (mega caps over $50B included).
The AAQS (AlleAktien Quality Score) is a criteria catalog developed and published by AlleAktien (https://www.alleaktien.com/aaqs) that checks 10 quality criteria on growth, profitability, and balance-sheet strength — 1 point per criterion passed, and a stock counts as a quality stock from 9 out of 10 points. This list is stricter than the methodology and shows only stocks with the full score of 10 out of 10 — our own back-test put the 10-point portfolio at 17.08% a year in the reliable window from 2010 onwards against 14.27% for an S&P 500 ETF, while the version from 9 points was only 0.77 percentage points ahead of the market. We calculate the score independently from our own fundamental data, with no partnership with AlleAktien. For criterion 4 (expected EBIT growth), we use the expected earnings trend as a proxy since EBIT estimates aren't available to us; where that doesn't hold up either — for instance with negative earnings per share — criteria 4 and 10 fall back to the revenue estimate. Where a company has been listed for less than ten years, we calculate the ten-year criteria (1, 3, 6, and 7) over the series available, provided at least 5 fiscal years are on record. Missing data counts as 0 points and is shown greyed out as "no data". Source: fundamental data.
Related scanners
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.